49,269 Shares in PROCEPT BioRobotics Corporation $PRCT Acquired by GSA Capital Partners LLP

GSA Capital Partners LLP acquired a new stake in PROCEPT BioRobotics Corporation (NASDAQ:PRCT) during the 2nd quarter, Holdings Channel.com reports. The firm acquired 49,269 shares of the company’s stock, valued at approximately $1,112,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Johnson & Johnson acquired a new stake in PROCEPT BioRobotics during the 2nd quarter worth $8,082,263,000. Handelsbanken Fonder AB boosted its position in shares of PROCEPT BioRobotics by 46.6% in the 2nd quarter. Handelsbanken Fonder AB now owns 26,100 shares of the company’s stock worth $589,000 after purchasing an additional 8,300 shares during the last quarter. Mirador Capital Partners LP acquired a new stake in shares of PROCEPT BioRobotics during the second quarter worth $441,000. Versant Capital Management Inc grew its stake in shares of PROCEPT BioRobotics by 994.5% during the second quarter. Versant Capital Management Inc now owns 1,193 shares of the company’s stock worth $27,000 after purchasing an additional 1,084 shares during the period. Finally, Militia Capital Management LLC acquired a new position in PROCEPT BioRobotics in the first quarter valued at about $863,000. 89.46% of the stock is owned by institutional investors.

Insider Activity at PROCEPT BioRobotics

In other news, CEO Larry L. Wood acquired 23,900 shares of the stock in a transaction dated Friday, August 7th. The shares were bought at an average cost of $20.85 per share, for a total transaction of $498,315.00. Following the purchase, the chief executive officer directly owned 23,900 shares of the company’s stock, valued at approximately $498,315. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last ninety days, insiders have sold 1,000 shares of company stock valued at $28,480. Company insiders own 4.00% of the company’s stock.

PROCEPT BioRobotics Price Performance

Shares of NASDAQ PRCT opened at $21.09 on Tuesday. The company has a debt-to-equity ratio of 0.15, a current ratio of 6.55 and a quick ratio of 5.35. The business has a 50-day moving average of $20.92 and a 200-day moving average of $24.39. The stock has a market capitalization of $1.21 billion, a price-to-earnings ratio of -10.87 and a beta of 0.89. PROCEPT BioRobotics Corporation has a fifty-two week low of $16.67 and a fifty-two week high of $42.43.

PROCEPT BioRobotics (NASDAQ:PRCT) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.01). The company had revenue of $94.50 million for the quarter, compared to the consensus estimate of $92.77 million. PROCEPT BioRobotics had a negative return on equity of 30.62% and a negative net margin of 32.53%.The company’s revenue for the quarter was up 19.3% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.35) EPS. As a group, sell-side analysts predict that PROCEPT BioRobotics Corporation will post -1.67 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on PRCT shares. Leerink Partners lowered PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $31.00 to $29.00 in a research report on Thursday, June 11th. Piper Sandler decreased their price objective on shares of PROCEPT BioRobotics from $35.00 to $25.00 and set an “overweight” rating for the company in a report on Wednesday, August 5th. Jefferies Financial Group restated a “hold” rating and set a $20.00 price objective on shares of PROCEPT BioRobotics in a report on Wednesday, August 5th. Citigroup downgraded shares of PROCEPT BioRobotics to a “hold” rating in a research note on Thursday, July 2nd. Finally, TD Cowen cut their price objective on PROCEPT BioRobotics from $34.00 to $28.00 and set a “buy” rating on the stock in a report on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, ten have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $28.00.

Key Headlines Impacting PROCEPT BioRobotics

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Positive Sentiment: Management is scheduled to present and hold investor meetings at the Baird 2026 Global Healthcare Conference in New York on September 15. The event could provide an opportunity to address demand trends and the company’s outlook, although no new financial information was announced. PROCEPT BioRobotics to Attend the Baird 2026 Global Healthcare Conference
• Neutral Sentiment: Multiple law firms reminded investors that September 22, 2026 is the deadline to seek appointment as lead plaintiff in a lawsuit covering purchases of PROCEPT securities from February 28, 2024, through February 25, 2026. The notices are largely duplicative and do not represent a new court ruling or finding of wrongdoing. Robbins LLP Encourages PRCT Shareholders to Contact the Firm
• Negative Sentiment: The securities-fraud allegations claim PROCEPT made material misstatements or omissions concerning product demand and inventory issues. One complaint-related notice alleges that an undisclosed handpiece discount program inflated recurring-revenue metrics and pulled demand forward; another links the disclosures to an approximately 18% stock decline. If substantiated, the claims could lead to litigation costs, damages, and increased scrutiny of the company’s sales practices and reporting. PROCEPT Securities Fraud Class Action Related to Inventory Issues

About PROCEPT BioRobotics

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.